U.S. Stock Night Market Movements

TriSalus fell 3.57%. Based on recent key news:

1. On May 13, TriSalus released its first-quarter financial report, showing a GAAP earnings per share of $0.03, exceeding expectations by $0.19, but revenue was $8.9 million, a year-on-year decline of 3.3%. This result put pressure on the stock price as the market was concerned about its revenue decline. Source: Business Wire

2. On May 13, Canaccord Genuity analyst William Plovanic maintained a buy rating on TriSalus and set a target price of $7. The analyst's positive rating failed to boost the stock price as the market remained cautious about the company's future growth. Source: TipRanks

3. On May 13, clinical evidence for TriSalus's PEDD technology showed significant clinical and economic benefits, supporting future growth. However, the market expressed concerns over its lowered short-term revenue guidance, leading to stock price fluctuations. Source: SEC 8-K report. The biotechnology industry has recently experienced volatility, with limited capital inflows.

Stocks with High Trading Volume in the Industry

Amgen fell 0.66% in the night market. Based on recent key news:

1. On May 14, Piper Sandler lowered Amgen's target price to $427. This move reflects market concerns about the company's future profitability, putting pressure on the stock price.

2. On May 14, Amgen reported strong first-quarter growth, primarily driven by Repatha and UPLIZNA. Nevertheless, the market remains cautious about its continued investment in pipeline products and tax issues.

3. On May 12, Amgen was listed as one of the high-yield stocks during inflationary periods. Despite this, analysts maintained a hold rating, believing there are better investment options. Inflation-resistant stocks are in focus, with increased market volatility.

Recursion Pharmaceuticals rose 0.66% in the night market. Based on recent key news:

1. On May 15, Morgan Stanley raised the target price for Recursion Pharmaceuticals from $5.00 to $5.50. This increase reflects market confidence in the company's future growth potential, driving the stock price up.

2. On May 14, trends in AI research in Silicon Valley showed strong capital support, with Recursion Pharmaceuticals benefiting as a participant in the AI field. The rise of AI self-improvement technology has attracted significant investor attention, enhancing market expectations for related companies.

3. On May 14, Recursion Pharmaceuticals' innovations and research in the AI field have garnered widespread attention. The company's research progress in AI safety and self-improvement has strengthened investor confidence in its technological prospects, further driving the stock price up The investment boom in the AI industry is driving up the stock prices of related companies.

Precigen fell 2.17% in after-hours trading. Based on recent key news:

1. On May 14, Precigen reported first-quarter revenue of $23.25 million, exceeding analysts' expectations of $20.80 million, with net losses narrowing to $7.93 million. This earnings report drove the stock price up by 23.8%. Source: Reuters

2. On May 15, Precigen announced that the sales performance of its flagship drug Papzimeos exceeded expectations, driving the company's revenue significantly up to $23.30 million, resulting in a 16% increase in stock price. Source: WSJ

3. On May 14, HC Wainwright & Co. raised Precigen's target price from $10 to $11, reflecting market confidence in the company's future growth. Source: Reuters The biopharmaceutical industry is experiencing strong growth, and market sentiment is optimistic